# A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

> **NCT02927873** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 107 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV (GSK3389245A) low dose formulation vaccine
- **BIOLOGICAL:** RSV (GSK3389245A) middle dose formulation vaccine
- **BIOLOGICAL:** RSV (GSK3389245A) high dose formulation vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02927873
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2019-02-19
- **Final completion:** 2020-11-26
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927873, "A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02927873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*